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A B S T R A C T
The objective of this study was to identify the pharmacological effects of bee venom and 
its major component, melittin, on the nervous system of mice. For the pharmacological 
analysis, mice were treated once with saline, 0.1 or 1.2 mg/kg of bee venom and 0.1 mg/kg 
of melittin, subcutaneously, 30 min before being submitted to behavioral tests: locomotor 
activity and grooming (open-field), catalepsy, anxiety (elevated plus-maze), depression 
(forced swimming test) and apomorphine-induced stereotypy. Haloperidol, imipramine and 
diazepam were administered alone (positive control) or as a pre-treatment (haloperidol). The 
bee venom reduced motor activity and promoted cataleptic effect, in a similar manner to 
haloperidol. These effects were decreased by the pretreatment with haloperidol. Both melittin 
and bee venom decreased the apomorphine-induced stereotypies. The data indicated the 
antipsychotic activity of bee venom and melittin in a murine model.
© 2014 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editora Ltda. All rights reserved.
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Introduction
The bee venom (BV) produced by Africanized honey bee-AHB 
(Apis mellifera L.) is a complex mixture of enzymes, lipids, 
amino acids, carbohydrates and peptides like apamin and 
melittin. It also contains dopamine and phospholipase A2 
(Hider, 1988; Sciani et al., 2010; Ferreira-Junior et al., 2010). 
Melittin constitutes 40 to 60% of dry whole honeybee venom, 
and this peptide has various biological activities, including 
high anti-inflammatory activity (Habermann, 1972; Gauldie 
et al., 1976; Son et al., 2007).
Experimental studies have shown neuroprotective 
effects of BV and melittin in amyotrophic lateral sclerosis 
(Yang et al., 2010; 2011) and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) model of Parkinson’s disease in 
vivo (Doo et al., 2010; Kim et al., 2011a; Chung et al., 2012; 
Doo et al., 2012; Cho et al., 2012) and against glutamatergic 
excitotoxicity in neuronal and glial cell cultures (Lee et al., 
2012). Effectiveness of BV acupuncture was also demonstrated 
for idiopathic Parkinson’s disease (Cho et al., 2012). 
The subcutaneous administration of BV has also been 
shown to induce the activation of catecholaminergic neurons 
in the arcuate nucleus in the hypothalamus of rats (Kwon 
et al., 2004) and in dopaminergic nuclei, including the 
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nucleus accumbens, substantia nigra, and locus coeruleus. 
When combined with acupuncture, it was able to reduce 
methamphetamine-induced hyperactivity (Kim et al., 2011b). 
In addition, it has been shown that BV exhibited no signs 
of toxicity when administered within a therapeutic range 
subcutaneously (s.c.) (Kim et al., 2004).
Despite the wide range of proposed uses for BV and melittin, 
the pharmacological effects in the central nervous system 
that result from their administration under physiological 
conditions have been poorly addressed. The development 
of new therapeutic approaches to mental disorders and 
neurodegenerative diseases remains a challenge. So, this 
study aimed to examine the pharmacological effects of BV and 
melittin in mice, with particular emphasis on dopaminergic 
related behaviors.
Materials and methods
Animals and ethical statements
Male Swiss albino mice (25-30 g) were maintained in a 
temperature and light cycle-controlled environment with free 
access to water and food. All procedures were in accordance 
with the standards of the Brazilian College of Animal 
Experimentation, and the experimental protocol was approved 
by the Ethical Committee for Animal Use of the Tiradentes 
University, Aracaju-SE, Brazil (approval number 010213).
Drugs
The bee venom (BV) was purchased from an apiary in the 
city of São Roque-SP, in the Brazilian Southeast region, 
it was obtained by electric extraction. Other commercial 
chemicals were used: melittin (Sigma®, São Paulo, Brazil), 
haloperidol (Janssen-Cilag Pharmaceuticals® Ltda, São Paulo, 
Brazil), Imipramine hydrochloride (Novartis Biosciences® 
S.A., São Paulo, Brazil) and diazepam (Union SA National 
Pharmaceutical Chemistry®, São Paulo, Brazil).
Assays
Pharmacological evaluation of the acute effects
The animals received vehicle, melittin (0.1 mg/kg) or BV (0.1 
mg/kg or 1.2 mg/kg). Both BV and melittin were diluted in 
saline [0.9%, 40 μl], administered subcutaneously (s.c.); the 
doses were chosen based on previous articles (Doo et al., 2010; 
Kim et al., 2011abc; Lee et al., 2001; Yang et al., 2010; 2011). 
Behavioral tests were performed 30 min after the treatments. 
The data were compared with the obtained after treatment 
with the antipsychotic haloperidol [0.2 mg/kg, intraperitoneal 
(i.p.)], imipramine (10 mg/kg. i.p.) and diazepam (1 mg/kg. i.p.). 
In the groups that received haloperidol and BV, haloperidol 
was injected 30 min prior the BV.
Catalepsy test
Catalepsy, defined as failure to correct an externally imposed 
posture, was evaluated according to the standard horizontal 
bar hanging test by placing the animals with both forelegs over 
a horizontal glass bar with 0.5 cm diameter, and 4.5 cm high 
from the ground (Sanberg et al., 1988). The time during which 
the mouse maintained this position was recorded for up to 
300 s, with three tries allowed to replace the animal in the 
cataleptic position. Catalepsy was considered to have ended 
when the forepaw touched the floor or when the mouse 
climbed the bar (Del Bel et al., 2010).
The open-field test
To evaluate the motor and emotional state, an open-field 
test was performed (Whimbey and Denenberg, 1967; Prut 
and Belzung, 2003). The following parameters were evaluated 
for 5 min: locomotion or crossings (number of line crosses), 
rearings (the number of times the mouse stands on its hind 
legs), grooming (the number of times the mouse “washes” 
itself by licking during the observation period) and time spent 
in the central area. The equipment was made of white colored 
wood, and it consisted of a quadrilateral with a rectangular 
area of 4830.25 cm2 and walls 34.5 cm high, with the base 
subdivided into sixteen quadrants (Hongxing et al., 2007; 
O’Leary et al., 2013).
Apomorphine-induced stereotipy
The apomorphine-induced stereotypies were measured by 
a score scale (from 0 to 6 where 0 = asleep or stationary; 1 = 
active; 2 = predominantly active but with bursts of stereotyped 
sniffing and rearing; 3 = constant stereotyped activity such as 
sniffing, rearing or head bobbing, but with locomotor activity 
still present; 4 = constant stereotyped activity maintained 
in one location; 5 = constant stereotyped activity but with 
bursts of licking and/or gnawing and biting; and 6 = continual 
licking and or gnawing of cage grids) after the application of 
apomorphine (20 mg/kg, s.c., Sigma-Aldrich Brasil Ltda., São 
Paulo, Brazil). Each animal was observed for 10 s intervals 
every 10 min for 60 min (Setler et al., 1976). The results were 
expressed as the mean sum of scores that were obtained for 
each group. 
The elevated plus-maze test
To evaluate possible action on anxiety, the elevated plus-
maze was used. The number of entries and the stay duration 
of the animals in the open and closed arms (Pellow et al., 
1985) were analyzed in an apparatus with a base 45 cm 
(height) from the ground, with two open arms (50 × 10 cm) 
and two enclosed arms of the same size, with walls 40 cm 
in height uncovered on the top. Each mouse was observed 
for 5 min.
The forced swimming test
The forced swimming test was carried out as previously 
described (Porsolt et al., 1977) in order to evaluate a possible 
antidepressant effect. The test consisted of two swim 
sessions separated by a period of 24 h. In the first session, 
the animals were placed in a circular water tank (30 cm high) 
for 15 min. After a period of intense movement, the animals 
acquire a posture of immobility, with minimal movements to 
keep the head out of the water. In the second session (test), 
the animals underwent the same procedure for 5 min. the 
swimming and immobility times were evaluated.
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Statistical analysis
After applying the Kolmogorov-Smirnov normality test, the 
gaussian data (mean ± standard error of the mean) of the 
catalepsy, open-field, elevated plus-maze and forced swimming 
tests were subjected to a one-way analysis of variance (ANOVA) 
followed by a Tukey post hoc test. Non Gaussian data (scores) 
from apomorphine-induced stereotypy were analyzed by 
Kruskal-Wallis test followed by a Dunn’s multiple comparison 
test. All statistical analysis was performed using SPSS Statistics 
19.0 software. Values of p < 0.05 were considered statistically 
significant. 
Results
Pharmacological evaluation of the acute effects
Cataleptic effect
The statistical analysis of catalepsy revealed a significant 
difference between treatments (F5-59 = 8.086, p < 0.0001; 
ANOVA followed by Tukey post-test), as illustrated in 
Table 1. The groups treated with 0.1 mg/kg of BV and melittin 
(0.1 mg/kg) recorded lesser time spent on the bar. In contrast, 
the administration of 1.2 mg/kg of BV induced cataleptic 
activity, an effect similar to that observed with haloperidol 
treatment. When the treatments were combined, it was 
observed that a lower dose of BV did not modify the action 
of haloperidol, while the administration of 1.2 mg/kg reversed 
the observed effects. The animals that received saline 
solution did not remain on the bar and thus were not subject 
to statistical analysis.
Group Treatment n Dose (mg/kg) Catalepsy (s)
1 Saline + Saline 5 - -
2 Saline + Melittin 6 0.1 1.9 ± 0.9
3 Saline + BV 5 0.1 2.5 ± 0.6
4 Saline + BV 6 1.2 87.2 ± 20.6b
5 Haloperidol + Saline 4 0.2 75.7 ± 28.8a
6 Haloperidol + BV 4 0.2 and 0.1 92.6 ± 16.7b
7 Haloperidol + BV 4 0.2 and 1.2 3.3 ± 0.6
The results are expressed as mean ± standard error of the mean (SEM).  
ap < 0.05 from groups 2; 3 and 7.  
bp < 0.01 from groups 2; 3 and 7 [one-way analysis of variance 
(ANOVA) followed by Tukey post-test].  
BV, bee venom, n, number of animals per group. The animals that 
receive saline solution did not remain on the bar and thus no 
statistical analysis was performed.
Table 1
Effect of bee venom and melittin administration on the 
catalepsy test.
Group Treatment n Dose 
(mg/kg)
Crossing
(5 min)
Rearing
(5 min)
Grooming
(5 min)
1 Saline 8 ----
164.0 ± 
12.7
32.6 ± 4.4 2.4 ± 0.3
2 Melittin 6 0.1
161.2 ± 
12.0
34.3 ± 2.1 1.1 ± 0.27
3 BV 5 0.1
139.8 ± 
11.6
7.6 ± 2.4b 1.2 ± 0.5
4 BV 6 1.2
44.8 ± 
14.7c
7.8 ± 4.8b 0.8 ± 0.31a
5 Haloperidol 4 0.2
65.0 ± 
22.6b
9.0 ± 3.6b 1.2 ± 0.2
6
Haloperidol 
+ BV
4
0.2 and 
0.1
140.7 ± 
10.2
6.0 ± 5.0b 1.5 ± 0.3
7
Haloperidol 
+ BV
5
0.2 and 
1.2
110.0 ± 
20.2
27.8 ± 15.5 1.2 ± 0.2
The results are expressed as mean ± SEM.  
ap < 0.05 from group 1. 
bp < 0.01 from groups 1; 2; 3; 6 (only in the groups unmarked with 
similar letter) and p < 0.05 from group 7.  
cp < 0.001 from groups 1; 2; 3; 6 and p < 0.05 from group 7 [one-way 
analysis of variance (ANOVA) followed by Tukey post-test].  
BV, bee venom, n = number of animals per group.
Table 2
Effects of the bee venom and melittin on the open-field test.
Locomotor and exploratory activity
In the open-field test, the administration of BV at a dose of 
1.2 mg/kg caused a significant reduction in the number of 
crossings compared to the other treatments. The same result 
was observed after the administration of haloperidol. This 
effect was not observed when the treatments were associated 
(Table 2, ANOVA followed by Tukey post-test, F6-34 = 14.122, 
p < 0.0001). When rearing was examined, both doses of bee 
venom and treatment with haloperidol resulted in a significant 
reduction compared to that seen in controls (F6-34 = 8.687, 
p < 0.0001, ANOVA followed by Tukey post-test). The 
reduction remained significant when the lowest dose of BV 
was preceded by haloperidol, but the effect was reversed in 
the group receiving 1.2 mg/kg of BV (Table 2). In addition, 
there was a significant decrease in grooming behavior after 1.2 
mg/kg of BV compared to the saline group (F6-34 = 3.525, p = 0.010, 
ANOVA, followed by Tukey post-test).
Neuroleptic effect
Both doses of BV and melittin decreased apomorphine-induced 
stereotypies (p = 0.006, Kruskal-Wallis test followed by Dunn’s 
multiple comparison test). However, there were no dose-
dependent effects (p = 0.82). The results are shown in the Figure 1.
70 Camila G. Dantas et al. / Rev Bras Farmacogn 24(2014): 67-72
Figure 2 - Effect of the BV and melittin on the elevated plus-
maze test. Mice received saline (40 μl), bee venom (BV) or 
melittin subcutaneous (s.c.) and diazepam (1 mg/kg, i.p.) 30 
min before the test. The percentage of entries (A) and time 
spent (B) in open arms are registered. Data are expressed as 
mean ± SEM. 
*p < 0.05 compared to other groups (one way ANOVA 
followed by Tukey post-test, n = 6-9).
Discussion
The results of this study showed that BV induced catalepsy in 
rodents, decreased apomorphine-induced stereotypies, and 
changed the parameters associated with motor activity in the 
open-field test. These effects were similar to the actions that 
described for the neuroleptic haloperidol, and a significant 
interaction was found when the bee venom treatment was 
combined with haloperidol.
The haloperidol-induced catalepsy is characterized by the 
occupation of striatal dopamine receptors (Sanberg, 1980). 
The finding of a cataleptic effect reduction associated to the 
treatments might suggest the occupation of these receptors 
by BV, and a competitive interaction of BV with haloperidol. 
The components that are present in BV have been related to 
dopaminergic transmission. Studies revealed that melittin 
decreases the uptake of dopamine by acting directly on the 
dopamine transporter, and inhibits the binding of D2 receptors 
with antagonist in cell culture (Keith et al., 2011; 2012). The 
other bioactive compound in BV, apamin, acts as a blocker of 
Figure 1 - The treatment with bee venom [(BV), 0.1 mg/kg and 1.2 
mg/kg, and melittin (0.1 mg/kg) decreased apomorphine-induced 
stereotyped behaviors in mice. BV, melittin or saline (40 μl) were 
administered 30 min before apomorphine (20 mg/kg, s.c.), and the 
measurements were taken for 10 s in intervals of 10 min for 60 
min. The results are expressed as mean ± SEM of 10 s counts. 
*p < 0.05 and **p < 0.01 from saline group (Kruskal-Wallis test 
followed by Dunn’s multiple comparison test, n = 8-12).
Anxiolytic effect
Regarding to the elevated plus-maze, the acute treatment 
with bee venom and melittin did not result in a significant 
effect on the assessment of anxiolytic activity. No changes 
were observed on the time spent in the open arms between 
the groups (F4-31 = 2.196, p = 0.096). Only the administration 
of diazepam significantly increased the number of entries 
into the open arms (F4-31 = 3.598, p = 0.018, one way ANOVA 
followed by Tukey post-test, Figure 2).
Antidepressant effect
Both doses of BV induced a significant increase in the 
immobility time observed in the forced swimming test, 
compared to imipramine (F4-30 = 3.219, p = 0.028, one way 
ANOVA followed by Tukey post-test, Table 3). From saline 
group, BV induced about 70%  increase in the immobility time, 
and melittin induced about 20%, although these differences 
were not found statically relevant.
Group Treatment n Dose  
(mg/kg)
Immobility  
time (s)
1 Saline 7 - 55.1 ± 25.7
2 Melittin 5 0.1 64.8 ± 14.3
3 BV 6 0.1 95.7 ± 15.7a
4 BV 6 1.2 99.5 ± 15.4a
5 Imipramine 8 10 27.4 ± 9.7
The results are expressed as mean ± SEM.  
ap < 0.05, bee venom (BV) groups compared to imipramine [one-way 
analysis of variance (ANOVA) followed by Tukey post-test]. 
Table 3
Effect of the bee venom and melittin on the forced 
swimming test.
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potassium channels and may cause an increased activity of 
dopaminergic neurons through D2 receptors (Vandecasteele 
et al., 2011). The microinjection of apamin in the nucleus 
accumbens of rats has been shown to produce increased 
motor activity and augmented brain levels of dopamine and 
its metabolites (Steketee and Kalivas, 1990). The behavioral 
effects were distinct to those observed in the open-field test 
in this study, nevertheless, it is noteworthy that the authors 
also observed a reversal by pre-treatment with haloperidol. 
Those findings are consistent with this study’s results that 
revealed that the administration of bee venom and haloperidol 
resulted in the reversal of the cataleptic effects, indicating that 
the active ingredients of bee venom may mediate the catalepsy 
that could be induced by D2 receptor occupancy. 
Since the modifications in the spontaneous motor activity 
may be mediated by D2 receptors (Zuo et al., 2008) while D1 
receptors are involved in grooming (Drago et al., 1999), the 
results point to an interaction of BV with the dopaminergic 
system. In agreement with this hypothesis, we observed a 
reduction in stereotypies induced by apomorphine after acute 
bee venom and melittin treatment. The stereotypy results 
from apomorphine interactions with dopamine receptors 
(Randrup and Munkvad, 1974) and it is a test frequently used 
for evaluating the properties of antipsychotic drugs.
To date, previous studies in the literature have investigated the 
effects of BV on behaviors related to pain and inflammation (Roh 
et al., 2006; Merlo et al., 2011), the prevention of amphetamine 
addiction (Kwon et al., 2010), and neuroprotective effects against 
neuronal death (Kim et al, 2011a). One study conducted (Kim et 
al., 2004) with lower doses reported no effects of the BV and 
its sub-fractions on sleep-induction time and duration, motor 
function in mice (rota-rod test), general spontaneous activity 
and pentyleneteterazole-induced convulsions in mice. An 
antipsychotic activity would be, therefore, a novel therapeutic 
effect of BV if lower doses are tested and proved efficient. 
More experiments with selective antagonists of different 
dopamine receptors are needed to elucidate the mechanism 
of action of the BV and melittin, but it is important to note 
that melittin displayed action on the apomorphine-induced 
stereotypies without side effects on motor performance 
or catalepsy with the dose tested. Neither BV nor melittin 
promoted depressant effect as assessed by the forced 
swimming test. It has been well demonstrated that drugs with 
antidepressant activity reduce the time during the animals 
remained immobile (Borsini and Meli, 1988). Thus, the results 
indicate a neuroleptic-like but not antidepressant effect for BV.
In addition, there was no effect of the BV and melittin on the 
anxiety parameters assessed by the elevated plus-maze test. It 
can indicate an absence of interaction with GABAergic system. 
Diazepam has been employed in behavioral pharmacology as 
a reference compound for potential anxiolytic-like substances 
(Mizushige et al., 2013). Here, it increased the number of entries 
in the open arms as expected. Although diazepam promoted 
an increase about 30% on the percent of the time spent in the 
open arms from the saline group, the statistical analysis failed 
to reveal a significant effect. This may be due the high SEM in 
the control groups and/or the reduced number of animals in 
some groups (n = 5-9).
Conclusions
These results indicate an interaction of BV with the dopaminergic 
system that might benefit the development of new BV-based 
strategies to treat mental disorders. Also, its major component 
melittin showed antipsychotic properties without the classic 
side effects of neuroleptic-like drugs. More studies are needed 
to elucidate the mechanisms of action of these compounds and 
its potential for future clinical applications. 
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